2-(3,5-dimethylisoxazol-4-yl)-N’,4’-dihydroxy-5-propyl-[1,1'-biphenyl]-3-carboximidamide | 1422018-30-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3,5-dimethylisoxazol-4-yl)-N’,4’-dihydroxy-5-propyl-[1,1'-biphenyl]-3-carboximidamide
• 英文别名: 2-(3,5-dimethylisoxazol-4-yl)-N',4'-dihydroxy-5-propyl-[1,1'-biphenyl]-3-carboximidamide；2-(3,5-dimethyl-1,2-oxazol-4-yl)-N'-hydroxy-3-(4-hydroxyphenyl)-5-propylbenzenecarboximidamide
• CAS: 1422018-30-1
• 化学式: C₂₁H₂₃N₃O₃
• 分子量: 365.432
• InChiKey: PJTLFUVNHMDECT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• NOVEL ESTROGEN RECEPTOR LIGANDS
  申请人：KARO BIO AB

  公开号：US20140323518A1

  公开（公告）日：2014-10-30

  Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R 1 to R 9 have meanings as defined in the Specification, are useful as estrogen receptor ligands.

  公式（I）的化合物或其药用可接受的酯、酰胺、碳酸酯或盐，包括具有规范中定义的含义的R1至R9的含义的酯、酰胺或碳酸酯的盐，可用作雌激素受体配体。
• Estrogen receptor ligand treatment for neurodegenerative diseases
  申请人：The Regents of the University of California

  公开号：US10758496B2

  公开（公告）日：2020-09-01

  The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

  本发明涉及使用雌激素受体β（ERβ）配体治疗神经系统疾病，如多发性硬化症（MS）和阿尔茨海默病。
• ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES
  申请人：The Regents of the University of California

  公开号：EP3189026B1

  公开（公告）日：2020-07-22
• US9586891B2
  申请人：——

  公开号：US9586891B2

  公开（公告）日：2017-03-07
• [EN] METHODS OF PROVIDING NEUROPROTECTIVE THERAPY RELATED TO ADMINISTERING AN ESTROGEN RECEPTOR BETA LIGAND<br/>[FR] MÉTHODES DE FOURNITURE D'UNE THÉRAPIE NEUROPROTECTRICE EN LIEN AVEC L'ADMINISTRATION D'UN LIGAND DU RÉCEPTEUR BÊTA DES OESTROGÈNES
  申请人：UNIV CALIFORNIA

  公开号：WO2017031276A1

  公开（公告）日：2017-02-23

  Provided are methods for treating a neurodegenerative disease, such as multiple sclerosis, in a subject who does not present with active lesions (e.g., gadolinium-enhancing lesions), comprising administering an estrogen receptor β ligand to the subject without conjointly administering a second immunotherapeutic agent. For example, any immunotherapeutic agent that the subject is receiving may be discontinued, e.g., upon determining that the brain of the subject does not present with active lesions. The method may include determining whether the brain of the subject presents with active lesions, e.g., by gadolinium-enhanced MRI.